Stem cells could treat patients with Type 1 diabetes thanks to a new implant – Digital Trends

vH7)`H.Exr]v[rU: RAU_D.H,U}_b-#>}?<.>|'jnP>N u$~Nf s=vy~hig~:#E8>:5jw_,'JXjE%ybyf]8x'bkrilv-N?EY0Em$ 8]L}W3 w,wIoa8o]uTkgjMhK<(hg~8l9n-o:KZqNqs (xy7`xah2l:$IKeY+OuFJq{Lg7 Ztb{; :[@s;vhxb^P!cxF}w&J?PA%/%X?u8]@a}7${g[ B'@7`#` qy=VVGS_O[,FNzFhcm -oS#b-MUI74vb$Mjjaa%EWbR%g~7}cOz.FOrxAC3/hFp>J =zc[o|(Vw9#W B$ -{mzN}5?>Y't&c?NYo-Va[0HX%[f9)v.W7m:b+, g7?kN.3t:zX]f)kzU qGwb7X 2l?z/= cVS[y=&zhsKRl+`r-+ -l?7;~,inz(ckF|cSGa Sb4jnd%!$F/^X*#j q#&wxi, '6R, gnMoJnphIVi 9_/y4U}ijtT#1#Ul~{-kFPfy)&KA{> KL]"RnE*#S/Ue'1|9_v]4yc]zc5B=M <%l|32=tc '28sC0,~|fc{68 'NdF{|ZCz^lrx5=<;%hjjVW_o|b}| J)@lr"B} rdSDL*Oyv,0=yX_-[MhM. 2 K$S;27 k& P&aO&+S,dho$'<6DVpDa;]j$I 5AliDq 3z0Yd4B*5)zZ*-TK;7v*CBVHq{n ^(WgUtTbv8Q 7jYq4[|yG?@m~KEU 5pF626Lgoz7OG9w,dD?7m;yYaxo;ulEx~4]7Bzv)A)uF|=T8~1^SDsX~K^Z~1W;No{kKosn]yAww$r>KZ.}?1OV0@Iv*|TwQ vNY`zo8vmakn3hCy+Lfrb:StN^y6YAUb{h >lI)B2`yRxFopDx?m:J!B_p`PA|h#an`Mzh,7Fv4CJ6.HQfHtuz(j[7g-RqGm[j~j)IIDb-"Aa57v7&u9a,)8[RT,d[CNmu@n;eR7mfwmmmsc{.$:;y([;yY<,NcQ @nnKA$(`%Wk6?_1!^WVjW{2C>~u6j6mIWV3'gG[oL4[6&[I#i~u1%{}pE&++9YKK/q';wjX~844=L258z/>W|/(^:Xk~jt[u6w5kuM[6*hLvvjhD|1oNWV5B#n6 PCq>m*U#h%Vv6_tSr<" *2q_p6 /]3_#iF}AnArMm[6[UNHft5Xnvi81(VD#@#w ^fY+9<.a7eV <, M9i~I_WLxZ;CVF !Z0ZY 5/j c>fbYA0?q$,Iy3H.t[$x4Y5Or$!djK`:=79lpOrj@L;b449' $F<4ZF g$a">ZP`K$ 5,N~kLT B%`2[!O4??|G./<5?fl< C@m ZW;53ior"Yz_= $1vp"]e5&+_ HmH_ "0p Jc@ZwY9 s(gtHkIs0@%ms *T9yL#jEiU[o0"zcuDO0 $eLP I|D'1evGd=L5W#Btn1Kk@s

l~.$;0Ng^)`9bC+=xp[e=w7E6O u0- 8xJt F FlkC15`3y)B_U*hS &~.@uEc6D *7LT":h'?IBL>8P4^/pa- "7Y~Bp^-yJc}ij~Rk^+IkP8yuEKdTpf1Js!U3x;-S9~AB>JV?'n id$Qrf'P6e[rHGUiE]0D~xmIR0 p{>P)%SA?hER{XO.B='Q,L#d,RIwT449;Mi (Dh=EkD;xC`:~"wnX$(] O7C _~?L!%zzz1_1bS"O:7Sm%qb}Vu%B,plp-H#dm%UjZJ /E8?uFs/j!m9oVUovE@E==0>_( %iOdbb: sX 3"^6aatX.yiLLc"y!sP0ldi'sXO),D1a|m!K)xBC#Veex.m d<.AL9qcLB h7%0OZ8"aW7a6bzNtiuxfec09H51XzX29$akK!hd >fl)/$">SO0FxY/Hmh w)m7O"(/K=2 ZpN4$Ua%nYBQvkqH!l-$Gg+1D[DM*E0cvK:awn&h/:zGE+{]w O-L!FzFsA->[^.858/k89)DxB"]4'~}PzaD$SH[SMB4|d&< 2"L;;"PrRYdg) eM (F|S{>_A%Gc$3&Ga"O Ix9Sq-v1GYalJqc05;/n"fo5W;{pu54mniOW/6E" d2kn{7JgqqwIdo22EpPvee$O`nI`G|, Y&q4?k+'bdp Yv[.kd:'qt"A$K%?d>S/c}GEG|%L" 9VVwM u=l_0<+F?3BFpU@j(BK_R`'rT~6r ~H_{uT9zr^f9@h*lk" %No/ 2M2Ps/:& $)C7Kd{jD$!l*ZiSkfSkh +F'!=--&WzU;5y`RZC7!`sn4Wk}U:Woiu8u0+pv3!W`*Kv D4)&8{*f8{>)|r(sv~~]"KNr}vL[TFA2rq9-DK19VFK,#?NNObU!"_7OG/Cj?hR*.b4q>Ic!Obh{%p;&v8!^=~4H~0[@!&O:/-SWaX 0|&JY@L yrq /_:u"|0aK/|g >0p5%U

bo"$dGB/.e*5 jT8/%SZ*J~YX1M)MQwJIAnv{y`~(zt"GszZGo4Z@=6Q]!`T QvN?sGI XQy8,tRt~;qxJRDI~+mF'%XXp!x.j6E"dmF.h2ot/p$%F`Yii`C8)HRP^KBQt8"7~X**RCT ;`=Bg *p+UZp]+%tvK,3RMA2E*q R5T h"))PaL@|fU65[5bP>@<5R~;jf8=isxQa=:*mmnll_ dQO0;0Sym%6xgEv{u?Q~lo%>G#=r{n@HUH)z6t1C:UC6jt /8'GoM/-)^/+; @8;u0 @m?A(5~KzD[| )j$|FaW] K[ |5nStGq^5Yc`>aUa:IF+Ob4ap+%LCoq*sGR 8 "7PwLc,jer"5l}s1[);2k\Z0rZug6O^5LbZN}EC. E^obxmaB=fYN}k#E*hK,HQ*'{CRxOlj7VtFFHW_bOrrt:J%*`J+.Rs^TCuP?Z O`,YUE,_=bf2CmaAB5Som24-0 U$}8C)FurW.HS (gj}9#*3j&c&+CMg09SdW~DJWm/tA~{%_5o9J<9OtFx2dIG0MQH$)M[YheTlSi0% aX/-%H$:3,TnfE0Fzu^LeE&Pj0'vBz#I9pWz(C/RHX:L*yBVS~B $G?$W_^ t{ggJAmDY-z +[F^E)'^=AS/,G.g-(5 _|JNQH.~1Zk$f>Oc2H_>CiQ8&l2u%N.Ea ZyX0 f}OOd=#^Y;K`kg<#xZ"SKWVC@8fY hv]Gkkp'z1Qm}s*IRkf'_m~BuyH73S:5+#qD< 7J1-h5Il7jb9SpheMG)44.)TUgsR,959 S;p< %~G1:`'XHxDV`p`!^Q:@S4O'xYw(rK?^Q=H?t0',OF*H#B#tt4?OB1L"IZn{AM)mDo]!J6{5Kuirtwd!F|; D,kx7dboj|FG 2t> ;w,Z#$N:>>9Y>Id$ } k!QZgdDS9z|b&A[("fkyg~E0CS#L1~H7#_!IZu231GR/>6,Tt^K*#,_A7L"X)} 4.% 6y&7}B)/}yYSo IHoMmGmS5e?4n=w G0O'[$3>b/<|A|5bWmTSdb@l"[OJnvU(X]vkks:Hgd#>WalTpIh.8Uup9A8'Ttskw&]Zu 'EY>&1i<$*L:A/$Sw{"F ?xV"G2tQQvfZ0P2Ve~~VDReKUH4'?[WPNU2kn*o`88XEH^l5Ou!6?DO[:X*FDy0S y2dwAVI $;'Y+JaW^PPLGg=Ov*sm*Wuz_nHc*ln"#aV[4dws @{lgT 9!^y ~UE )R]a|#x$=9:4n8$/Y{ka+'IdZ$$q+[c`WqXevvPDhNu`Q{e/U Vp~nzInl@ }* Syuzlw,2XXPUG0bFk@%=dX ~nH.rm DVY ~wEyvo}B3y^e9Gve $"Y0lup s&)bBb:_na~$sNU 7,[O,Rluz5]J;)%@F0nzLe"C} F60g"mcvz"RS^omg dY.*X, D Tt9 .H'IDy(wAW#g^?L|PXk;wJV'w74FIBe[T]+ kl.oe-`BzpSa1i<9U]5%9( DoC}Ejl1QEErWYd [-a+yfLE:y&.Bq'@&e:X--Z~!C )*aC_MOgSDU*% z^(dcNjtECXM{ sN -~I6F7*D`Q AQGG})T/cb3`4'3Iz@88 ;ph1[ydQ:j'WHO:JT$oo{l5gog}UyQNNNZEyd7Y0&9:@!*A A, !idL?<_`E*c6+ n LH }xBRbP :Pl9h.])R Q luK(IKEWWuKPztuBZ$7U'BVus3F% {#n[ovurP0,(Db)m3?$DX*yH6Svdt+C}t}GdPI!)=$C(a"HBmTd)2ndXlpP&J@^_V_S8aYh+%uyRL25[@n`-lVL4,04opCg4:dZRzXOf>l c-qv,(hXCx$E#]bp,nd$d5Rlh7w79*lf0 ]mkV[vEU.%Y$*q-M-2Y[R8mE&`t$o"Vb1zEh8KfSt Sst]H&N(m%=V: d!I?^VES3EmV0{-ZYMnw/`_393dq[t__x-Nf/3sZ-j{GK*4Y-q;HinNX_- SiefC ]H&}%(|bH:tx{WeYzwJ2uY9e(OJvf0mWRJJ|v,4g&[[;@nG: SG[7Oo8&pv>`]Q}.w2InHx_e]) si%U- :3WN,Yp6F#IRAjY>e=L"[ );?*HBH$TU6xqD:6jpl);5VSvC$UV2/jyI:6jpXG2K)+c%Fn58i84i8:piYl%9u0I]rofb,n4q:19[ ASGy3 p%|T6vQMQGQ7@o)o{hXf6O*ps8bK`B_=56,9 kX+,P4!JVK~K9p@*Wij.L|,5Tvg)oXqcqHa(Y UM=v8aH? )V1SF53vr7`T*F.rl;q*+O}T?4'>Nk-=J[(+&17ZThF-~,L=] JXzdL!,AYp|FLx%eL94 4_!4 -C-|>N _ 2:F6yD(T<3@xP?VEQ/X9", ^#"Ew+q!QPeP.1f )xqr Qh ;wbi:Zy3*zL)KHP/zY5>eU8m7|8q1YA]Jp8!k$MB9tpV:SDNQQ}gDda&q}}zfwCF o L"hsn=.@}|g8nq4Ea**WVFN*rM3Aeqc%C"{;_,Y/5j9}8^ TQvZg|r)-$=u4q7T&G%kj2tAardz#qO)&lE&+)=Cr}ew {T>SEIi_0[^s R tQl q9 s )J> jy7Jj(QG:Khdc Z'{e4Jyv+C*^@@*C}-5t(]@1|b4F& I+(ux])#fQ&3u~||#ki(VBH=tC5}r.Ht3Cw,en>#acqd2'3V&.k{y u9W~? {A af Gf1W@~L8F[h;02Yo7Fr(@zBadyg^y+L+h%q"rBR%FL=Q:N17oa }<<, [))pYEa|aBBTpxvhFsFd)(v$+Z0gXoOp>:[N 7pdKgv< dk1 %hsYI9g|1,R` 4ZlcMvs11y[G8r1doCY +!@>xRB"yu,e9bIi2)x !#Nl%w 8lDSphGJKL$-ol i96T "8; CDy2gP0O *j;2@Y$)AD(_z?Bs@6cB4O~!OT D1}$)mvR"n(nAqXC:pC;e.CR7h(aqT4/IgH bDit?g,dRjR}-FNd7 -7v!x; zOE6'C1nyD>$M(Ef{^$h3BJ$;`%A |YOA O*$*II`um[l z:ecbSCSowFa8JS%F0s)A.S, P4x4N4@PLTrEQ]B$I #e`gb1>rCV07S@L(AXG3L# AfB*EE+-uoFO*3NC{4`l4?He%ljcri.^r;#)?G:7+k1u?st+Bb5(l;;8r o5bcO:y$BE9-h#gBJ~2(I4%$9 "+t9H&`q>GeF'^IA&meE~)~)Q26w0E]t>8X8 Q@iuB*&AP^0nSi3Z>x, BV,of7zDLo~;;~q5Fl'$QHu{c2}(dB?#Kb_) ":E$LB#T(/F@!@,&@hYr2BrZ"`J;Ggnq,KR 2g22+z@glkMXo#b7WbW! |(_CDpjI;q;3C@{bXrl+I :_aGI_5jlRYt^BTo8BgLI]mm6:F}._o)_a q&F8H$}RSmjUw>h 3z)m?I}@bK_|@6fDLW32F7TnzosEgp,x"=M^fnPx;SOgaVO(7'{PI5>o:N0!D9L@zGf~3g&qh#*Eb f[OTj/Uih09oqZ- uiJj`KSYPfcmcE&8$un2 Kkzu(EPr"$;}>nOAxE5qvpq7*P#90(0C;d uVb1#z1q9U7Hs2>/ 6) B|92|1z64B+!|P^X>+0^I/G$M[F$LSkqy=[{Y{z*h@!UK0L|H_'>Z6B[U>J5(VnQ`aa'FI[+Ru^a`U1#$(;ne 6; u"2&kP@*N@oi/ KnUq6s"T fF&d# AK[(X}I@ty?8EF;E>xNL`@oK)loV Euj7p {8Z,r'9B ?Qx;nQb+pb1o> [ Kj=Uo C_.Ev(nkh :-dY,QsU=IU~_Sc iX/5%K-_s4K:!7sIJ`B2CUZqH- LBt|.j T/Ocq6FF!4gqIwR)aH)9}U)+g@UJQ.o#'r`Mm{f`KA]@i*12} *]w3p4v==l<:!gpWNqa*`M;F1"1vA.Vh>(>d;rBU:YL.o_&9]?} M}ad'!CKF#!AdgEr/2#)7)-" r$ <'H@7C)6fEh6J990Jq ^l67F;2aH@G6x`l91"2C[Gd=Nr!#!c[iH7FD<Ue0(h8o.U/N6dc)m17DQ g^WL';ugXbaH%/b>oLtk8XEzi(-G+*67%?K|C$(;pm2H(P73ajUe1M 5~pH2.7CHdo(XG9@Ey$T,C&6x7=Lf>I(UMA"O@kV(rpbGTYHtD)DKP~>U4iogr-Bzf)0212i.%$eB J.&]22Z-G Gofqgb:raL, b&KrvnG=[`q1xkK'Gb='y]:/*U>!-%4%U~J]n 3if8bD2~ zM#n'HP-|o|7&QrzW`R,u$-Zg 4)oF:m1u?8fGx$v?,(4g,Pa-twoXR ~xbo$XQbfT d4Dwqq"3 @2I|{Poe$$Y-erTft-{ w6mw>Fw&v5$>D=-Y Q ztS P%ZuL"p[`yqaji>Q:~8o'$#6H<7aa1E?/&wsVqF`G5!ze[2W@;s+{#B cxH;(=P'nb *p5td95q_@kHD&| <6(3# iGP<3eo<0Q3c|cZsF^O}{U43@z6xOSXsOd rhkem$acH #x5mCjn$GI>('@fVJ-=pe~m]CmsY,04`ryR) GFdW(%]ab #>Q4ijk?fKW)b}Mo#ndc'V|~|sp1'& gS3}~{1~1to'/G%-4@lB5:m9]LtyH|v| cJ]d]f=$`yKQI1(Rc$/DPCf3TjryQJE kUxQ=WUi57DGkdAut_M]f:o9 UF%Zk.^^S1qJ1cn_ ;:okME7%r30o@KyWtclXcx#3n.:[2i?nq)N^|:4iq+W{?Er'>:{lhVJLSSH.&U?oUH>[d?[c^1zN!-REx[|axuun*W BQB{F-*6p2bLwR?FY:WF+vV`WTONMCL.$~.=> oFAE?J/HTY0iN0/m|O|7^[4k_|DU9Sn&6bJvyR|&7+u,b5*/s5fRJ]-|tL9J{_,Rc_[YagohO-^~80Xal~m0p^6;A{5%t@ w10f/R&*Kp :Tsq iKR6o0#1s%!M `QfI!a3Bw|Ct>y r>Zxn%yreV|Its/yiMwjRY| ;]p6D,]iKgp'J+k[,-R'l:HTQ0Y&PJv%f~O*30zYY759w DZ.a@{I9o`yu A$S6i ij/mkU p6z) i?rDk_R(^,te^zMO{Cn`E/@3k-t|M%m:#BBmGM2@F/T-J=cN;8^qPVNMb91_'l?!9i4NOF(N}L$WW+40TchE [;M+)azo_8}}}%cJ[-;#:idISry6?*[|^5v%Z;S~RjKuu fEZW0,I3V=4.d}d2W(?2A?/v5Z]~)P8{?cRpupeQ6` 9D.u]/w' R~uD)qip #I/xOe25'lv$^;Y~!"+QHAdq]n$vm;4>ji+J3u}"3*cr~>E/=pO>~ m* 4G1n0%,DyvTwZvP2]Y[v#dz>32 lCy@vuVy%X }k:dqT)M=K!eQ8rYK]D$JMWk)UqA_oje .-be:MfPZi=,Zf376[zEfV*K0HIDgmty lEkyz="?34zdNs8,+%W4H'XRU1=/+R3501`G:f0 jty$|XE,#}b'UZzQ0o/h-]%ew88sw^maz{Wj7{p(cHgj~Ou" c-u*;={0uz:RN;G0~t K9Se1KL!d&IzrvQTi^d)vOvjyH'{*pc+} OLOTq0,iWYF+~QAWvN~R m!/2V ti) E'=Bi?T5N!rNj{TD!Xl$vgidIrJf[k6sH6AB8}0%;N}zw9d1 V/6GER`v= bKEc@W|f6ja]Q$8q"e=F+kR>E}v>cZh'M2o|[_FejLBGag-U[#riRC^MS:Xp}h|: plL>~ize&ab6Cp{qe_{5k&U!:E4;hp8qaLV:a^a=O:P.x%dC ~ocY%'h,#@,}Gu_BP!* ?]g7.y$J3_4{Kc%>'i"5!"wBbqiaXCWLgt@@9n)BJ(S WW^c*90M=k^{y77@rX[R[bLHD[_XfIDA^@g(k#IN<ZAN+K_L]N..)@s 2,B,?Yjr_$;Td>1QTk,X[X+O'VdV=W;~ me:-H:z* . Y]t9w.OB:1Nzj#[ptAz)qw"LfyvdYWPAS#rDy;H /G8OJcnWk$W,$z.! F1Kf'1/Kn?gBq{>kM|peQ.Ts .}+^-:-XUc?PWv}1LkUv=sl~`|tq *EJy[R3tZz}L= db ;Vx)9adANt,cL.ScLp_v2Dih7;4]!DvueUa+ >5>!/$n=W+G7@\,c~%cKF]|6s=3&Ap5+#7d` fj:NR|C5}L|]C:wXT6D` r2;!hPmpN=/Ss#o &eZy?Kxr}wvjjt[` n@@B_i_L0gg"?Tc["Neh2W'_/`'lB%R@I!5c(M^`pgc'hd)U[QUf$SEbNoZ{ e). =#=F1y:n Q1QjMR7DN0/H4H_gq~x|6bwKg$FwRKfL8VD'|~ZZ7Rg9EH rU25{y~hmW;8V2P8-*4|x08_dky4s6hhr%,"v{s4)]WspSG= 8&#oa/zBFx4fe{w'*ngz5=qZR}Y6!aM8Nt 6l4srODo3!|_Mws2nz==r"&OQ !z"@9"1E%g. KLSsBGw"9k{Z'UI N VDd7/q/*H 8Y'O;I>iL6J#z95+3cU.bML*c+>JmI!9d5y}3@!M;Q|>"olY4,z.=;P}; |mmM!Lp;]d;IX?hwU+LZe/)IASSuS9$ q59NLCV95V 'Q,6d5;L{ulujrjE-F>8Twuri<6k>RQ,srwv0PPPvQCu+NbuXMoZg~AI6H a <(K>[nKa+fZga|3/Xz]F Omp=^poTn0v#I'pFtWCLd(-I<<']aQ7stbdB!@B8P1^>Ncg^j/.M`S+Ui<8%5 PgnmW`lsg-YapfTdc`g;m/0L]H@QF*Ad95lw{H`A<,fK[{J;|L_SZ=QwW3w;)y?{LN2=xs=/)Iw:'GAw~UKOB7j5P`d|9+^Hd_385dFa< U<2w-4^0:o_}X/QlgU;m8:5iQnvF)#0qT/;..i'VM+J3m:LMf?G>Vp1Upfvd,. xsb;E:p,e0 /JT~[VIf6I{~Yv-Out@Z74Br tkTwbG 7vCDjE=g;@wl.pq9mY],YL0^^.k{vKke=|vm{wZjPt8ETdrD0M(kPW@>1[oFzU -yp5=RG !8t>42."[g|c88SL? Ss>bXym}lE:NDN7ag#{F.RH|_vmG]Aq2z9"#%-? ytb7S~g0D%"T`2f%Y|{mBc1yLm83ZN6bcEqM*tGDSj>u8RP?=p;KxGd `rl=2f1[;sJE#=TgGo/q,Xuc58GS"M|pa%i'[fD3gj$;* nA$(jt!GS6vlxTEXBXNc6B;927dErEuTuQZD`r!F/(kkFb1(?M;M{%B8/Uv0c",{ZqkV9 Tq2QfUQ,Hs^"F5D`_N9r3t`y^Tz^|{!dg WZwWX+]^+@CHo-W2datI63GiOfchlp`}E>BKcgde_%MJB@F[amC}?3 NGQho{a'PR,=%zNVFAV=;6vSsR6K}bkgpYL.*-g@`sRFEv9e]JY.H$p{BiT@KSTQu]MbK.h*")xJ[n'"9 .r'h RT eqqeE .ZTZ*{w4e%4TubFHm~ZM! qL7HfVtrPid{_Fz+W^A( )[8gS(f|JWs?1u]5SAIc|"nI/x!lik A.6#p=6S| %#UpIkP550ka 8N,l, yZYJI^1TL8~8MkZ)#%g!uizF^D :!K&jG.| {`9 D!eCuU_ $ 0xh$RC5|9^ |b;U[AVgD DMrweC-9Ic`|fD$A2=:A7Cw{>IQ E11,7"I7YXdFZWk ;=D-/Zcd5=_[`S!d {*2*5e e(CB">>zr5l"DpovdE.^f1eY;P;rBdO$36W~m_7[[cR:l.Xen` *~U :pdUR`"|.4pn9ltu,4;9we,eNs r[)0wcUE] j&T (,O]r.$"8r4bgPMeGe{JrY/-}!;# vmn&* 2V?e@X,(;9UHM ;X =&-IAT+eEztDl}'J' 5FZj{/{edr-LkM3`;7;'~JB_t/el>NcKWA|j9scYt]ofE=E V5Uy6)|obB`alk[Ne^?M&[u9"rFDE(63 anak(g4l3]w ct0.cp5:2'zN0;ucGNA3vW1e *Q|MrrX9.] 4!bUT_,KVx j^(yXH}$1|iG2W L3JkQq VAqN'mhS`_1u5uJ]"JoU}N@DN!c{+(r1'k+egbxl[Son([-_.lj[vq]-]sh6HDQ,gGZ9$E" 1A&hkYsVn$u;;3 ]*H*r?[S?n",BV-)(,3M!Tx$]s0+#%l-t-KH-5 sZeUO:PZ>ILJe{Agi;eF[adi4 8F`S}hf&p] C(m2UM,(I9iNj Ywd[ughaAW*.xKwvAQ0KXKits1nH>|6mNb2#2;oQBW/+e$7*sa8$?DCTq+kc4:&I6r./2u9p=fxQQLaq+kY-P1qy5VrZze u $n/h-%A&9RaE8H6{4rGxj;-?(rXZ:q[US1s$*W-8S7L^#qYVP)9<^^.k{vrjS/Wwvugo[eW_1W)rja;s2NujuOy/& S1{y_ow^e.S;9!?b=;_n8|`RIuGM!2{mqIxE p H H59Ed_}h0I'&DcS1.iP'?(aNoKk._?oh||i|RcI~e_$L <]=+~!]a?Q=6fm00#yfKS-}g/*lh<3=H];x}fr9:5 ZcP^ 'eoZS<{(}wnO&'z9;4})'*[6o"_o9DOh_}z:sro5:'/p22p zF1nDGrz[~wz2g-X>&q5KQ}r>@|]S?g7}1r[K7*R"w;|j+77+Q3H*#QoR6pmi5r}iC&qsrs5Cl'deWQswNdx lqx:Md#"v2m%K%yoZzxb+YWG n} Vw< D[[[ (;yl7l]}i1g1"o"YPmi{cjJ[K')qfkGvoX61%[F%O|Z/'.;ol/y W?aGodR#B;YZ=S5}=Ff==>@{B7uk06QqyII>-e/sno=pe{enu_MovzAe]=S0zS===K'{G'Lo~:6^ou;n]Zin~rLV_tN^$&V 9zSE rB[kNU5?I/rTT?X|io7 nsJVy,EJ.<: G7Vo27^M`xLB`{/,e205HVxHM&GO;EF}Mk:}yp9>eS?8<5/4@PMf ?s7U:ja=$+{BS_;<|CLjO|&.;:,w~F)C4^p-ghD}n#Q.?]PXZGxv}kzaMsSm>'&6;8SL$3|21Hhl&0]}fl8{FFC_< _}u;f yQg*O7?x)@HDH!6g8g~Y *a5YR]{}}eG& >ccU;U@mw5;c.t54enq2o=3lqT=ZJ

View original post here:
Stem cells could treat patients with Type 1 diabetes thanks to a new implant - Digital Trends

Hope for Emma’s voice: Child undergoes ground-breaking stem cell treatment – Stillwater News Press

DUNCAN, Okla. Emma Harper is closing out her summer with a ground-breaking stem cell treatment.

Cerebral Palsy and a Broad Spectrum Genetic Disorder create roadblocks in different forms for this 10-year-old Horace Mann student.

Her parents, Micah and Tara Harper, accompanied Emma on the trip to Orange, Calif., for the stem cell treatment if an effort to improve their daughter's life.

We never gave up hope that she would one day be able to speak, Micah said. We were told by doctors whenever she was much younger that she should probably be institutionalized, that she wouldnt walk, she wouldnt talk. She really has beat the odds. She can walk. She can walk on her own...

Emma continues to break through barriers in new and different ways.

Tuesday, Aug. 1, 2017, Emma and her parents met with Dr. Henderson, who is familiar with the Southwestern Oklahoma area, having been stationed at Fort Sill.

An initial meet and greet and question and answer portion of the procedure was completed. The Harpers were scheduled to go back the very next day for Emmas treatment, which usually lasts around two hours ended.

For Emma, whosebody accepted the vitamins and stem cells quickly, the treatment only took 20 to 30 minutes.

They (doctors) said whats happening is that her body is really accepting the stem cells. The doctor said that its like fireworks going off in her body right now, explained Micah. It was a really quick procedure, and the doctor said that within the next two weeks shes going to really start feeling the effects. We will see progress in two months, and she could continue making progress for two years.

There is no telling what type of progress Emma can expect.

Her body is dictating where the stem cells are going," Micah said.

Emmas doctor has seen miraculous recovery and progress in children with cerebral palsy. This treatment also has been used in early-onset dementia. The treatment has a 100 percent success rate with varying specific points of progress within the body.

While the Harpers cannot be completely sure this phenomenal treatment will give Emma her voice, other positives of the procedure could be highly beneficial.

It was a gamble that we were willing to take, Micah said.

Emma was feeling great and enjoyed sightseeing in Los Angeles Thursday after her treatment.

Arrington writes for The Duncan Banner, a CNHI News Service publication.

Read more:
Hope for Emma's voice: Child undergoes ground-breaking stem cell treatment - Stillwater News Press

How to keep your stem cells young – The Garden City Telegram

Stem cells are the highly versatile spare tires of your body. Once called on, they can replace a damaged cell and, because they aren't yet directed to become part of a specific organ or tissue type, they not only could become (metaphorically speaking) a new tire, but could also fix a worn-out engine part or a cracked windshield. It just takes the right prodding in the body, or the laboratory! They can do it even after being inactive for a long time.

Those remarkable abilities are promising to provide scientists with a powerful tool to use in conquering disease. That's because normally, cells in organs such as the heart and pancreas do not divide to repair damage that might happen to the organ. But manipulation of stem cells ... well, that could allow doctors to induce self-repair in many parts of the body. No more heart transplants; bye, bye diabetes, macular degeneration, spinal cord injury, osteo- and rheumatoid arthritis. We might even repair third-degree burns and stroke damage that was previously considered permanent.

That promising future became more hopeful in 2006, when researchers figured out how to turn specialized adult stem cells (replacing use of embryonic cells in some research) into what they called "induced pluripotent stem cells" (iPSCs). Since then, the number of experiments using iPSCs has sky-rocketed: Adult mouse stem cells are injected into the damaged ventricular wall of a mouse heart and the stem cells regenerated damaged heart muscle! There have been a few, small, human-based studies that, says the National Institutes of Health, have "demonstrated that stem cells that are injected into the circulation or directly into the injured heart tissue appear to improve cardiac function and/or induce the formation of new capillaries." But and this is a big but they caution, "significant technical hurdles remain that will only be overcome through years of intensive research."

Tip: Stem cell clinics promising miracle cures are not a good idea at this time. The International Society for Stem Cell Research says: "Many clinics offering stem cell treatments make claims that are not supported by a current understanding of science."

Fortunately, there's a lot you can do to keep your stem cells healthy and your RealAge younger.

1) Protect your skin from excess sun exposure; use micronized zinc oxide 30 SPF sunscreen. Exposure to ultraviolet radiation from the sun and tanning beds and lamps is a leading cause of melanoma. New research shows that the trigger may be stem cells gone wild; melanoma may be related to the formation of carcinogenic stem cells.

2) Avoid hormone-disrupting chemicals such as BPA in plastics and phthalates in household goods and products. One study found that they disrupt development of stem cells needed for sperm production.

3) Don't overeat; eat whole foods, not chemicals. Steer clear of processed foods that dose you with preservatives, colorings, emulsifiers, added sugars and syrups. Continuous intake of sugary foods reduces stem cell vitality! A lab study found that reducing caloric intake by 20 percent can positively boost stem cell activity. We say, try it five days a month.

4) Get regular exercise. According to a new study out of the University of Rochester, loss of muscle stem cells is the driving force in loss of muscle tone and strength as you age. That makes it increasingly important to get two to three 30-minute sessions of strength-building exercises weekly. Aerobic effort (push it a bit) stimulates some stem cells to produce bone instead of fat.

5) Avoid excess radiation. Exposure to a dental X-ray, PET or CAT scan provides diagnostic benefits without immediate risks. But new evidence shows that accumulative exposure to radiation over a lifetime can have damaging effects on stem cells and organs. Opt for an MRI, not a CAT scan when possible; refuse dental X-rays unless necessary; follow guidelines for mammograms. And make sure your imaging center is accredited, personnel are credentialed, and they use weight-based and indication-based protocols.

Mehmet Oz, M.D. is host of "The Dr. Oz Show," and Mike Roizen, M.D. is Chief Wellness Officer and Chair of Wellness Institute at Cleveland Clinic.

See the original post here:
How to keep your stem cells young - The Garden City Telegram

Ohio State researchers report breakthrough in cell regeneration – The Columbus Dispatch

JoAnne Viviano The Columbus Dispatch @JoAnneViviano

In what researchers consider a major scientific leap, a team at Ohio State University has discovered a new way of turning skin cells into any type of cells the body might need, a technology that has limitless potential, from regenerating a wounded limb to repairing a brain after stroke to healing a damaged heart.

The process involves placing a square chip about the size of a fingernail on the skin, adding a droplet containing genetic code, and zapping it with an energy source.

While it hasn't been used in humans yet, the process was used in animals to heal the brain after stroke and to generate blood vessels in legs that had been cut in the femoral artery, the limbs major blood supply, said Chandan Sen, the director of the Center for Regenerative Medicine and Cell-Based Therapies at Ohio State's Wexner Medical Center.

In leg experiments involving mice, researchers placed the chip on the animals' wounded legs, delivered the appropriate genetic material, and saw blood vessels grown to regenerate limbs within seven to 14 days, Sen said. Legs that otherwise would have turned black and required amputation were pink, and the mice were able to run again.

In brain experiments on mice, the chip was again placed on the leg, different genetic material was dropped on, and neurological cells grew in the area. Three weeks later, scientists detected firing neurons, and the new cells were taken from the leg and inserted into the brain.

The leg-healing process was duplicated in pigs after the Walter Reed National Military Medical Center expressed interest. Sen said the technology could be used to heal troops in the field. One caveat: It must be deployed within 72 hours of a limb being damaged.

Twenty-six researchers from the fields of engineering, science and medicine worked together to made the technology a reality.

Join the conversation at Facebook.com/columbusdispatchand connect with us on Twitter @DispatchAlerts

The discovery could have countless applications across various medical disciplines, Sen said. He's hopeful other researchers will help stretch the impact of the device.

"There are many smart minds throughout the country and the world that will take this and run," Sen said.

Sen expects that human trials will come soon, after a letter on the research is published Monday in the Nature Nanotechnology journal. The research was led by Sen and L. James Lee, professor of chemical and biomolecular engineering in Ohio States College of Engineering.

Sen said it takes less than a second to deliver the genetic code that spurs the skin cells to switch to something else, then several days for new cells to grow.

The equipment needed can fit in a pocket. And the process can be done anywhere; no lab or hospital is needed.

The black chip, made of silicon, acts as a carrier for the genetic code.

"Its like a syringe thats the chip but then what you load in the syringe is your cargo," Sen explained. "Based on what you intend the cells to be, the cargo will change. So if you want a vasculogenic (blood vessel) cell, the code would be different than if you wanted a neuro cell, and so on and so forth."

The genetic code is synthetically made to mirror code from the patient.

The electric field pulls the genetic material into the skin cells.

Because the research project had a high risk of failure, and because Ohio State wanted to keep it close to the vest, public money was not sought, Sen said. Instead it was funded by university and philanthropic money from Leslie and Abigail Wexner, Ohio States Center for Regenerative Medicine and Cell-Based Therapies and Ohio States Nanoscale Science and Engineering Center.

Approval from the federal Food and Drug Administration is required before Sen, Lee and the research team can try the technique in humans. He expects to get that approval and prove human feasibility within a year. Sen's hopeful, then, that "the floodgates will open" and the technology will be used widely within five years.

The chips are already being manufactured locally due to an assist from the Rev1 Ventures business incubator on the Northwest Side, and the technology has gained interest from Taiwan-based Foxconn Technology Group.

Lee called the concept very simple and said he was surprised by how well it worked.

He had developed similar technology prior to 2011, but it only worked on individual cells and only in processes separate from the body. Since then, he said, many researchers and companies have approached him to come up with a system that worked on tissue in the body.

"More and more people said, 'This technology can be very, very powerful if you can do tissue,'" he said. "It turns out that it works. It was very surprising."

This version, he said, is a very significant advancement and is "much, much more useful for the medical applications."

jviviano@dispatch

@JoAnneViviano

Read the original post:
Ohio State researchers report breakthrough in cell regeneration - The Columbus Dispatch

World’s first method for mass-producing platelets from iPS cells unveiled by Kyoto startup – The Japan Times

A Kyoto-based medical startup said Monday it has developed what it believes to be the worlds first method for mass-producing blood platelets from induced pluripotent stem cells, better known as iPS cells, opening new possibilities for controlling bleeding after accidents or surgeries.

Platelets are used to minimize bleeding and are made from donated blood.

Megakaryon Corp. teamed up with a group of 15 other Japanese companies for the iPS cell project, including the Otsuka Pharmaceutical group and Sysmex Corp., to develop a cheaper method to mass produce platelets.

Genjiro Miwa, CEO and founder of Megakaryon, said the consortium plans to get approval to sell and distribute the product in Japan and the United States by 2020 and hopes to expand its use in other nations. Clinical trials in Japan and the U.S. are expected to begin next year.

Shinya Yamanaka of Kyoto University received the Nobel Prize in Physiology or Medicine in 2012 for creating iPS cells, which can develop into any type of cell in the body. These cells hold great promise in the field of regenerative medicine and drug development.

Speaking to The Japan Times, Miwa said that around 800,000 platelet transfusions take place annually in Japan, generating a market worth around 73 billion. He said the market is around three times that size in the U.S. Once the new technology gets the green light, the consortium hopes to produce iPS-derived platelets to meet roughly 10 percent of that annual requirement, Miwa said.

The company said Japans aging population and low birth rate have raised concerns about the long-term supply of platelets provided through donations alone.

Our aim is to fill the expected shortage of platelets, Miwa said.

Platelets play an important role in the blood-clotting process. While donated platelets have a shelf life of only four days, Megakaryon says those made from iPS cells can be stored for two weeks. It says the technology will also lead to cheaper production of platelets.

The new technology is based on techniques developed by Professor Hiromitsu Nakauchi of the University of Tokyo, and Professor Koji Eto of Kyoto University.

Megakaryon, founded in 2011, obtained the exclusive rights to use the patents on the technologies and has been conducting research to enable mass production of platelets.

Miwa said his company is already capable of producing enough platelets to help several patients each week, but that he hopes to boost output by a factor of 1,000 through partnerships with major pharmaceutical firms and other companies.

Other members of the consortium include Satake Chemical Equipment Manufacturing, Nissan Chemical Industries, Kawasumi Laboratories and Kyoto Seisakusho.

Last week, Kyoto University said its researchers are set to begin the worlds first clinical trial of a drug to treat a rare bone disease called fibrodysplasia ossificans progressiva (FOP) a disorder in which muscle tissue is gradually replaced by bone, inhibiting body movement. The drugs effectiveness was confirmed in conjunction with the use of iPS cells.

Continued here:
World's first method for mass-producing platelets from iPS cells unveiled by Kyoto startup - The Japan Times

Cellect Engages Locust Walk to Support Business Development Activities for Cellect’s ApoGraft – Markets Insider

TEL AVIV, Israel, August 7, 2017 /PRNewswire/ --

Cellect Biotechnology Ltd. (NASDAQ: APOP, TASE: APOP), a developer of stem cell selection technology, announced today that Locust Walk was engaged to seek strategic licensing deals and global pharma partnerships in order to kick-start the commercialization of Cellect's ApoGraft as an innovative platform for stem cells selection for all indications and from all sources of cells. Among others, the Company believes this platform is expected to become a major cornerstone development tool for both pharma companies and medical research centers through licensing of Cellect's IP.

Locust Walk's mandate is to identify relevant licensors and assist Cellect in closing potential licensing deals and strategic business collaborations with pharma and medical device companies as well as research and clinical centers that may potentially result in licensing of AppoGraft for stem cells based therapeutics R&D purposes.

Cellect's ApoGraft technology can be utilized immediately to help thousands of research centers globally engage in adult stem cells based therapeutics by providing them with a simplified and cost efficient method to isolate stem cells for use as a raw material for a wide range of stem cells based therapeutics. Before Cellect's ApoGraft, such procedures were extremely complex, inefficient and required substantial resources in both cost, time and infrastructure. ApoGraft will be used to significantly advance the use of stem cells across multiple therapeutic indications as well as research and biobanking purposes.

Cellect's CEO, Dr. Shai Yarkoni commented, "Similar to the successful collaboration Cellect has with Entegris (NASDAQ: ENTG), we intend to secure our capabilities to supply all of the players in the stem cell field with the capabilities to produce and sell stem cell based medical products for a multi-billion dollar market. Cellect intends to become a major player in this fast growing field and therefore we are committed to a global scale campaign for business development with our new partner - Locust Walk."

Cellect chairman, Mr. Nuriel Chirich Kasbian stated, "After years of work, we are close to realizing the first commercial applications of ApoGraft. We chose Locust Walk to help us unlock the value of ApoGraft for both medical research companies and shareholders."

About Cellect Biotechnology Ltd.

Cellect Biotechnology is traded on both the NASDAQ and Tel Aviv Stock Exchange (NASDAQ: "APOP", "APOPW", TASE: "APOP"). The Company has developed a breakthrough technology for the isolation of stem cells from any given tissue that aims to improve a variety of stem cells applications.

The Company's technology is expected to provide pharma companies, research centers and hospitals with the tools to rapidly isolate stem cells in quantity and quality that will allow stem cells related treatments and procedures. Cellect's technology is applicable to a wide variety of stem cells related treatments in regenerative medicine and that current clinical trials are aimed at the cancer treatment of bone marrow transplantations.

About Locust Walk Locust Walk is a leading life sciences transaction advisory firm focused on biopharmaceutical and medical technology companies. Its team of experienced professionals fuels the growth of promising companies at every stage by connecting the right products, the right partners and the most attractive sources of capital - driving innovation for growth and transformative results. Locust Walk was founded in 2009 and currently has offices in Boston; San Francisco; Tokyo, Japan and Cologne,Germany. Over the past two years, Locust Walk has completed many transactions for its clients around the world. For further information, please visit http://www.locustwalk.com.

Forward Looking Statements

This press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in this press release when we discuss our expectation regarding the market opportunity of ApoGraft potential licensing and other collaborations, our beliefs about the future integration of our technology into the production procedures of stem cell-based products, the potential of our technology and its proposed uses. These forward-looking statements and their implications are based on the current expectations of the management of the Company only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in Cellect Biotechnology Ltd.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2016 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, http://www.sec.gov, and in the Company's periodic filings with the SEC and the Tel-Aviv Stock Exchange.

Contact: Cellect Biotechnology Ltd. Eyal Leibovitz, Chief Financial Officer http://www.cellect.co +972-9-974-1444

SOURCE Cellect Biotechnology Ltd.

Read more:
Cellect Engages Locust Walk to Support Business Development Activities for Cellect's ApoGraft - Markets Insider

First implants of stem-cell pouches to ‘cure’ type 1 diabetes – New Scientist

Stem cells have been cultured to treat many different of conditions

Lewis Houghton/Science Photo Library

By Andy Coghlan

Last week, two people with type 1 diabetes became the first to receive implants containing cells generated from embryonic stem cells to treat their condition. The hope is that when blood sugar levels rise, the implants will release insulin to restore them to normal.

About 10 per cent of the 422 million people who have diabetes worldwide have type 1 diabetes, which is caused by the bodys immune system mistakenly attacking cells in the pancreas that make insulin. For more than 15 years, researchers have been trying to find a way to use stem cells to replace these, but there have been several hurdles not least, how to get the cells to work in the body.

Viacyte, a company in San Diego, California, is trying a way to get round this. The firms thumbnail-sized implant, called PEC-Direct, contain cells derived from stem cells that can mature inside the body into the specialised islet cells that get destroyed in type 1 diabetes.

The implant sits just below the skin, in the forearm, for example, and is intended to automatically compensate for the missing islet cells, releasing insulin when blood sugar levels get too high.

If it works, we would call it a functional cure, says Paul Laikind, of Viacyte. Its not truly a cure because we wouldnt address the autoimmune cause of the disease, but we would be replacing the missing cells.

The device has already been safety tested in 19 people with diabetes, using smaller numbers of cells. Once implanted, the progenitor cells housed in the device did mature into islet cells, but the trial didnt use enough stem cells to try to treat the condition.

Now Viacyte has implanted PEC-Direct packages containing more cells into two people with type 1 diabetes. A third person will also get the implant in the near future. Once inside the body, pores in the outer fabric of the device allow blood vessels to penetrate inside, nourishing the islet progenitor cells. Once these cells have matured which should take about three months the hope is that they will be able to monitor sugar levels in the blood, and release insulin as required.

If effective, it could free people with type 1 diabetes from having to closely monitor their blood sugar levels and inject insulin, although they would need to take immunosuppressive drugs to stop their bodies from destroying the new cells.

If successful, this strategy could really change the way we treat type 1 diabetes in the future, says Emily Burns of the charity Diabetes UK. A similar way to treat the condition with pancreas cells from organ donors has been in use for nearly 20 years, successfully freeing recipients from insulin injections, but a shortage of donors limits how many people are able to have this treatment.

This isnt a problem with stem cells. The embryonic stem cells used to make the progenitor cells originally came from a spare early stage embryo donated by a woman who was having IVF. Because embryonic stem cells, and the progenitor cells made from them, can be multiplied in limitless amounts, Laikand says that, if the treatment works, the method would be able to treat everyone who has the condition.

A limitless source of human insulin-producing cells would be a major step forward on the journey to a potential cure for diabetes, says James Shapiro at the University of Alberta, Canada, who has collaborated with Viacyte on this project, and who pioneered the donor pancreas method decades ago. For sure, this will in the end prove to be a durable landmark for progress in diabetes care.

More on these topics:

Read the original:
First implants of stem-cell pouches to 'cure' type 1 diabetes - New Scientist

Breakthrough Stem Cell Study Offers New Clues to Reversing Aging – Singularity Hub

What causes the body to age?

The Greek Philosopher Aristotle thought it was the hearta hot, dry organ at the seat of intelligence, motion and sensation.

Fast-forward a few centuries, and the brain has overthrown the heart as master of thought. But its control over bodily agingif anywas unclear. Because each organ has its own pool of stem cells to replenish aged tissue, scientists have long thought that the body has multiple aging clocks running concurrently.

As it turns out, thats not quite right.

This week, a study published in Nature threw a wrench into the classical theory of aging. In a technical tour-de-force, a team led by Dr. Dongsheng Cai from the Albert Einstein College of Medicine pinpointed a critical source of aging to a small group of stem cells within the hypothalamusan ancient brain region that controls bodily functions such as temperature and appetite.

Like fountains of youth, these stem cells release tiny fatty bubbles filled with mixtures of small biological molecules called microRNAs. With age, these cells die out, and the animals muscle, skin and brain function declines.

However, when the team transplanted these stem cells from young animals into a middle-aged one, they slowed aging. The recipient mice were smarter, more sociable and had better muscle function. Andget thisthey also lived 10 to 15 percent longer than mice transplanted with other cell types.

To Dr. David Sinclair, an aging expert at Harvard Medical School, the findings represent a breakthrough in aging research.

The brain controls aging, he says. I can see a day when we are implanted with stem cells or treated with stem cell RNAs that improve our health and extend our lives.

Its incredible to think that a tiny group of cells in one brain region could be the key to aging.

But to Cai, there are plenty of examples throughout evolution that support the theory. Experimentally changing a few of the 302 neurons in the nematode worm C. elegans is often sufficient for changing its lifespan, he says.

Of course, a mammalian brain is much more complicated than a simple worm. To narrow the problem down, Cai decided to zero in on the hypothalamus.

The hypothalamus has a classical function to regulate the whole bodys physiology, he says, so theres a natural logic for us to reason that the hypothalamus might be involved in aging, which was never studied before.

Even so, it was a high-risk bet. The hippocampusbecause of its importance in maintaining memory with ageis the most popular research target. And while the hypothalamus was previously somehow linked to aging, no one knew how.

Cais bet paid off. In a groundbreaking paper published in 2013, he found that a molecule called NF-kappaB increased in the hypothalamus as an animal grew older. Zap out NF-kappaB activity in mice, and they showed much fewer age-related symptoms as they grew older.

But heres the kicker: the effects werent limited to brain function. The animals also better preserved their muscle strength, skin thickness, bone and tendon integrity. In other words, by changing molecules in a single part of the brain, the team slowed down signs of aging in the peripheral body.

But to Cai, he had only solved part of the aging puzzle.

At the cellular level, a cornucopia of factors control aging. There is no the key to aging, no single molecule or pathway that dominates the process. Inflammation, which NF-kappaB regulates, is a big contributor. As is the length of telomeres, the protective end caps of DNA, and of course, stem cells.

Compared to other tissues in the body, stem cells in the brain are extremely rare. So imagine Cais excitement when, just a few years ago, he learned that the hypothalamus contains these nuggets of youth.

Now we can put the two threads together, and ask whether stem cells in the hypothalamus somehow regulate aging, he says.

In the first series of experiments, his team found that these stem cells, which line a V-shaped region of the hypothalamus, disappear as an animal ages.

To see whether declined stem cell function contributes to aging, rather as a result of old age, the researchers used two different types of toxins to wipe out 70 percent of stem cells while keeping mature neurons intact.

The results were striking. Over a period of four months, these mice aged much faster: their muscle endurance, coordination and treadmill performance tanked. Mentally, they had trouble navigating a water maze and showed less interest in socializing with other mice.

All of these physiological changes reflected an acceleration in aging, Cai and team concluded in their article.

And the consequences were dire: the animals died months earlier than similar transgenic animals without the toxin treatment.

If the decline in stem cell function is to blame for aging, then resupplying the aged brain with a fresh source of stem cells should be able to reinvigorate the animal.

To test this idea, the team isolated stem cells from the hippocampus of newborn mice, and tinkered with their genes so that they were more resilient to inflammation.

We know the aged hypothalamus has more inflammation and that hurts stem cells, so this step was necessary, explained the authors.

When transplanted into middle-aged mice, they showed better cognitive and muscular function four months later. Whats more, they lived, on average, 10 percent longer than mice transplanted with other cell types. For a human, that means extending an 85-year life expectancy into 93. Not too shabby.

But the best was yet to come. How can a few cells have such a remarkable effect on aging? In a series of follow-up experiments, the team found that the pool of biological molecules called microRNAs was to thank.

microRNAs are tiny molecules with gigantic influence. They come in various flavors, bearing rather unimaginative names like 106a-5p, 20a-5p and so on. But because they can act on multiple genes at the same time, they pack a big punch. A single type of microRNA can change the way a cell workswhether it activates certain signaling pathways or makes certain proteins, for example.

While most cells make microRNAs, Cai found that the hypothalamus stem cells have a unique, very strong ability to pack these molecules up into blobs of membrane and shoot them out like a bubble gun.

Once outside the cell, the microRNAs go on a fantastic voyage across the brain and body, where they tweak the biology of other tissues.

In fact, when the team injected purified little bubbles of microRNAs into middle-aged mice, they also saw broad rejuvenating effects.

Cai explains: we dont know if the microRNAs are pumped out to directly affect the rest of the body, or if they first act on different areas of the brain, and the brain goes on to regulate aging in the body.

Even so, the aging field is intrigued.

According to Dr. Leonard Guarente, an aging biologist at MIT, the study could lead to new ways to develop anti-aging therapies.

Whats more, its possible the intervention could stack with other known rejuvenating methods, such as metformin, young blood or molecules that clean out malfunctioning cells.

Its possible that stem-cell therapy could boost the hypothalamus ability to regulate aging. However, scientists still need to know how stem cells link with the hypothalamus other main role, that is, releasing hormones.

Of course, injecting cells into the brain isnt a practical treatment. The team is now working hard to identify which of the thousands of types of microRNAs control aging and what exactly they do.

Then the goal is to validate those candidate anti-aging microRNAs in primates, and eventually, humans.

Of course humans are more complex. However, if the mechanism is fundamental, you might expect to see effects when an intervention is based on it, says Cai.

Stock Media provided by digitalreflections / Pond5

Visit link:
Breakthrough Stem Cell Study Offers New Clues to Reversing Aging - Singularity Hub

Surgeons focus on stem cell transplants to help save sight of acid attack victims – Evening Standard

Eye doctors are fast-tracking efforts to improve stem cell transplants to save the sight of people blinded in Londons acid attack epidemic, the Standard can reveal.

Research at The Royal Free Hospital aims to boost success rates, particularly where cells are taken from deceased donors at present, three-quarters of such transplants fail.

Corneal stem cell transplants have been used for some time on acid victims, including model Katie Piper.

But they are difficult and risky to perform, with doctors hampered by a shortage of donated eyes.

They are most successful when one eye is damaged and cells can be transplanted from the healthy eye. This works in about seven out of 10 cases.

The success rate is about 25 per cent when both eyes are damaged and cells are harvested from the eye of a deceased donor.

Consultant ophthalmic surgeon Alex Shortt, who is carrying out the research at the Royal Frees institute of immunity and transplantation in Hampstead, said the aim was a success rate of 95 per cent. The work is being funded by the Wellcome Trust and Moorfields Eye Charity.

A total of 454 acid attacks were reported to the Metropolitan police last year, almost three times the number in 2014. Mr Shortt said: The last six to 12 months has seen demand for these treatments rise hugely.

He said the challenge was to remove scar tissue without creating a new scar as the eye healed. A sample of healthy corneal stem cells are grown in the laboratory to form a sheet, which is attached to the surface of the damaged eye to enable the cornea to regenerate.

The success rate is about 68 per cent. It fails in three out of 10 people. They regrow a scar and they go blind again, Mr Shortt added.

We are trying to move to the point where we can use donor cells and prevent the body from rejecting them. Then we can treat patients more cheaply, and have a bank of cells ready to go as soon as we see a severe injury.

Next week NHS rationing body NICE is due to decide whether to approve an 80,000 Italian stem cell treatment, Holoclar, that works for seven in 10 patients. However, it is only effective where cells can be taken from the patients undamaged eye.

NICE is likely to require patients to undergo a cheaper treatment first.

Medics are also appealing for more people to donate their corneas after death. NHS Blood and Transplant said more than one in 10 donors place restrictions on the use of their eyes, the most for any organ.

About 70 corneas a week are needed but 50 are donated. Hundreds of corneas are imported from the US and Europe.

The rest is here:
Surgeons focus on stem cell transplants to help save sight of acid attack victims - Evening Standard

Researchers Use Simpler, Safer Method to Obtain Stem Cells for Treating Lung Diseases – Cystic Fibrosis News Today

A new method of isolating lung stem cells could help speed the development of stem-cell based therapies for lung diseases, including cystic fibrosis, according to a University of North Carolina study.

That method is extracting them with a tube from the mouth to the lung rather than surgery. The team has already used the method in their pulmonary fibrosis research work.

The new study, Derivation of therapeutic lung spheroid cells from minimally invasive transbronchial pulmonary biopsies, was published in the journalRespiratory Research.

Doctors can use stem cells to restore injured lungs, but obtaining and maintaining the cells is challenging.

Not only do they need a lot of lung tissue to extract the stem cells, but the way they have obtained the tissue with surgery is highly invasive. This has led to high death rates among patients who have had the biopsy surgery.

Still, isolating the cells for stem cell-based therapies is a good way to treat many lung diseases.

Until recently,University of North Carolina Health Careresearchers used lung tissue biopsies to obtain stem and support cells that they can cultivate for treatments. They discovered thatlung spheroid cells can help regenerate the lungs of mice with pulmonary fibrosis.

The team is now using a relatively non-invasive procedure, called a transbronchial biopsy, to isolate lung spheroid cells while reducing the risks associated with obtaining them by surgery. In this procedure, a lung pneumologist inserts a thin, lighted tube, or bronchoscope, through a patients nose or mouth to collect several pieces of lung tissue.

This is the first time anyone has generated potentially therapeutic lung stem cells from minimally invasive biopsy specimens, Dr. Jason Lobo, an assistant professor of medicine at the university, said in a press release.

We snip tiny, seed-sized samples of airway tissue using a bronchoscope, said Lobo, a co-lead authoer of the study. This method involves far less risk to the patient than does a standard, chest-penetrating surgical biopsy of lung tissue.

They were able to obtain more than 50 million lung spheroid cells from one small piece of isolated tissue. When they injected the cells into mice, they were delighted to find that the cells ended up in the animals lungs.

These cells are from the lung, and so in a sense theyre happiest, so to speak, living and working in the lung, said the other co-lead author, Dr. Ke Cheng. He is an associate professor in the universitys Departments of Molecular Biomedical Sciences and Biomedical Engineering.

In a second study, published in the journalStem Cells Translational Medicine,researchers highlighted lung spheroid cells potential to treat cystic fibrosis. Injecting the cells in rats with cystic fibrosis significantly reduced their lung inflammation and scarring, compared with control animals.

Also, the treatment was safe and effective, whether the lung spheroid cells were derived from the recipients own lungs or from the lungs of an unrelated strain of rats, Lobo said. In other words, even if the donated stem cells were foreign, they did not provoke a harmful immune reaction in the recipient animals, as transplanted tissue normally does.

Scientists have had discussions with theU.S. Food and Drug Administrationabout clinical trials of lung spheroid cells as a pulmonary fibrosis therapy.

Cells isolated from patients own lung tissue would eliminate the risk of the body rejecting the stem cells. Such treatments require a lot cells, however and doctors might opt to harvest some from healthy volunteers and whole lungs obtained from organ donation networks.

Our vision is that we will eventually set up a universal cell donor bank, Cheng said.

The researchers hope that some day their stem cell therapycan be used in other lung diseases, including cystic fibrosis.

Read more from the original source:
Researchers Use Simpler, Safer Method to Obtain Stem Cells for Treating Lung Diseases - Cystic Fibrosis News Today